Available in 10 mg, 20 mg and 60 mg vials, in lyophilized form.
Retatrutide is a synthetic peptide characterised as a triple agonist at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCGR) receptors.
Its triple-receptor profile distinguishes it from single and dual incretin agonists, making it a reference compound in research into combined incretin and glucagon receptor signalling. Published work examines receptor binding selectivity, downstream cyclic AMP response, and energy expenditure and substrate utilisation endpoints in preclinical models.
Areas of published research
- Diet-induced obese rodent models, with reported endpoints in body weight, fat mass and lean mass retention
- Energy expenditure and substrate utilisation measured by indirect calorimetry
- Hepatic lipid content and steatosis markers in preclinical models
- Comparative receptor potency against single and dual incretin agonists in cell assays
For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.


Reviews
There are no reviews yet.